Biomea Fusion, Inc.
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for metabolic diseases, especially diabetes and obesity. The company’s core technology is its proprietary FUSION™ discovery platform, which it uses to design covalent small molecules intended to create deeper and more durable biological effects than conventional non-covalent drugs. Its pipeline currently includes icovamenib and BMF-650, both still in development and not yet commercialized. Biomea has not generated product revenue, has no sales force, and remains dependent on external financing, collaborators, and third-party development and manufacturing partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInvestigational medicines in preclinical and clinical development, including icovamenib, BMF-500 and BMF-650.
The proprietary FUSION™ System used to identify and optimize covalent small molecules.
Internal and outsourced drug discovery, testing, and clinical development activities.
Customers
Biomea does not currently sell commercial products, so it has no traditional end-customer base today. Its near-term economic counterparties are collaborators, clinical trial sites, contract research organizations, contract manufacturing organizations, and potential licensing partners that support development and eventual commercialization. If its candidates are approved, the end customers would be patients with metabolic diseases such as diabetes and obesity, with prescribing and reimbursement decisions influenced by physicians, payers, and health systems. Because the company has no sales force or distribution infrastructure, future commercialization would depend on either partners or the buildout of its own commercial organization.
CROs, trial sites, and CMOs that Biomea pays to run studies, test materials, and manufacture clinical supply because it lacks internal commercial-scale infrastructure.
Biopharma partners that may receive commercialization rights or help fund development in exchange for milestones, royalties, or shared economics.
Patients with diabetes, obesity, or related metabolic conditions who would use the company’s oral therapies if approved.
Prescribers and reimbursement decision-makers that would determine uptake, access, and pricing power after approval.
Strategy
Biomea’s strategy is to advance its FUSION™ platform into differentiated oral small-molecule therapies for metabolic disease, with a focus on icovamenib and BMF-650. The company is using a capital-efficient, outsourced development model, relying on CROs, CMOs, and research partners rather than building a large internal manufacturing footprint. It is also pursuing regulatory milestones, including IND clearance and Phase I execution for BMF-650, to validate the platform and expand the pipeline. Longer term, Biomea may monetize assets through partnerships, licensing, or, if successful, internal commercialization, but all of these paths require substantial additional capital.
Clinical proof-of-concept is needed to validate the platform and create partnering or commercialization value.
The company has no product revenue and needs capital to fund trials, manufacturing, and operations.
A broader pipeline can diversify scientific risk and improve long-term value creation.
The company may either partner assets or build its own sales and marketing capabilities if approval is achieved.
Geography
Biomea is headquartered in the United States and its business is organized around U.S.-based research, development, and financing activities. The company also relies on third-party manufacturers and service providers outside the United States, including in China, which creates operational and supply-chain exposure. Because it is still pre-commercial, geography matters more through where development work is performed and where suppliers are located than through revenue generation. The company has not disclosed country-level revenue because it has not yet generated product sales.
Risks
Biomea faces the classic risks of a clinical-stage biotech company: no approved products, no revenue, and a heavy dependence on future trial success and regulatory approval. Its business model also depends on third-party CROs, CMOs, and suppliers, including single-source and non-U.S. providers, so any disruption can delay trials, increase costs, or impair supply of clinical material. The company has disclosed substantial doubt about its ability to continue as a going concern without additional financing, making capital access a central risk. More broadly, competition in metabolic disease is intense, and even if candidates succeed clinically, Biomea would still face pricing, reimbursement, manufacturing, and commercialization risks.
- Need for additional capitalImpact: CriticalLikelihood: High
The company has no product revenue and expects to require substantial additional funding to continue development and operations.
Exposure: Corporate funding and program continuity
- Clinical and regulatory failureImpact: CriticalLikelihood: High
Drug candidates must succeed in trials and obtain FDA and other approvals before any revenue can be generated.
Exposure - Third-party manufacturing and supply disruptionImpact: HighLikelihood: Medium
The company relies on CROs, CMOs, and single-source suppliers for materials and testing, creating delay and quality risk.
Exposure: Clinical supply and development timelines
- Commercialization capability gapImpact: HighLikelihood: Medium
Biomea currently has no sales force, marketing, or distribution infrastructure.
Exposure: Post-approval launch execution
- Competitive pressure in metabolic diseaseImpact: MediumLikelihood: Medium
Larger companies and alternative therapies may outcompete Biomea on efficacy, safety, timing, or reimbursement.
Exposure: Diabetes and obesity markets
Accounting
Judgemental itemsExternal trial, manufacturing, and lab costs are expensed as incurred, so timing of vendor work directly affects reported losses.
Impact: Quarterly operating expense volatility
Management must estimate services received but not yet invoiced, which can change reported liabilities and expenses.
Impact: Expense and balance sheet estimates
Equity awards are a common compensation tool in clinical-stage biotech and can be a significant non-cash cost.
Impact: Operating loss and dilution analysis
The company has disclosed substantial doubt about continuing as a going concern without new financing.
Impact: Liquidity and valuation assessment
Similar listed companies
Publicly listed companies with a comparable business focus.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
iBio, Inc.
IBIO · Pharmaceutical Preparations
BioVie Inc
BIVIW · Pharmaceutical Preparations
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026